Alzheimer's disease research and development: a call for a new research roadmap

被引:31
作者
Feldman, Howard H. [1 ]
Haas, Magali [2 ]
Gandy, Sam [3 ,4 ]
Schoepp, Darryle D. [5 ]
Cross, Alan J. [6 ]
Mayeux, Richard [7 ]
Sperling, Reisa A. [8 ]
Fillit, Howard [9 ]
van de Hoef, Diana L. [10 ]
Dougal, Sonya [11 ]
Nye, Jeffrey S. [12 ]
机构
[1] Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC, Canada
[2] One Mind Res, Seattle, WA USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] James J Peters VA Med Ctr, New York, NY USA
[5] Merck & Co Inc, N Wales, PA USA
[6] AstraZeneca Pharmaceut LP, Wilmington, DE USA
[7] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA
[8] Harvard Univ, Sch Med, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA
[9] Alzheimers Drug Discovery Fdn, New York, NY USA
[10] New York Acad Sci, New York, NY USA
[11] NYU, Langone Med Ctr, Steven & Alexandra Cohen Vet Ctr, New York, NY USA
[12] Johnson & Johnson Innovat, Janssen R&D LLC, Titusville, NJ USA
来源
ANNALS REPORTS | 2014年 / 1313卷
关键词
Alzheimer's disease; dementia; research and development; therapy; treatment; economics; epidemiology; DEMENTIA; BIOMARKERS; CASCADE; HEALTH; BRAIN; IVIG;
D O I
10.1111/nyas.12424
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Epidemiological projections of the prevalence ofAlzheimer's disease (AD) and related dementias, the rapidly expanding population over the age of 65, and the enormous societal consequence on health, economics, and community foretell of a looming global public health crisis. Currently available treatments for AD are symptomatic, with modest effect sizes and limited impact on longer term disease outcomes. There have been no newly approved pharmaceutical treatments in the last decade, despite enormous efforts to develop disease-modifying treatments directed at Alzheimer's-associated pathology. An unprecedented collaborative effort of government, regulators, industry, academia, and the community at-large is needed to address this crisis and to develop an actionable plan for rapid progress toward successfully developing effective treatments. Here, we map out a course of action in four key priority areas, including (1) addressing the fundamental mechanisms of disease, with the goal of developing a core set of research tools, a framework for data sharing, and creation of accessible validated and replicated disease models; (2) developing translational research that emphasizes rapid progress in disease model development and better translation from preclinical to clinical stages, deploying leading technologies to more accurately develop predictive models; (3) preventing AD through the development of robust methods and resources to advance trials and creating fundamental resources such as continuous adaptive trials, registries, data repositories, and instrument development; and (4) innovating public/private partnerships and global collaborations, with mechanisms to incentivize collaborations and investments, develop larger precompetitive spaces, and more rapid data sharing.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 24 条
[1]  
[Anonymous], J NUTR HLTH AGING, V17, P774
[2]  
[Anonymous], 2010, International statistical classification of diseases and related health problems, 10th revision
[3]   Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease [J].
Bateman, Randall J. ;
Xiong, Chengjie ;
Benzinger, Tammie L. S. ;
Fagan, Anne M. ;
Goate, Alison ;
Fox, Nick C. ;
Marcus, Daniel S. ;
Cairns, Nigel J. ;
Xie, Xianyun ;
Blazey, Tyler M. ;
Holtzman, David M. ;
Santacruz, Anna ;
Buckles, Virginia ;
Oliver, Angela ;
Moulder, Krista ;
Aisen, Paul S. ;
Ghetti, Bernardino ;
Klunk, William E. ;
McDade, Eric ;
Martins, Ralph N. ;
Masters, Colin L. ;
Mayeux, Richard ;
Ringman, John M. ;
Rossor, Martin N. ;
Schofield, Peter R. ;
Sperling, Reisa A. ;
Salloway, Stephen ;
Morris, John C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) :795-804
[4]   Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro [J].
Cattepoel, Susann ;
Schaub, Alexander ;
Ender, Miriam ;
Gaida, Annette ;
Kropf, Alain ;
Guggisberg, Ursula ;
Nolte, Marc W. ;
Fabri, Louis ;
Adlard, Paul A. ;
Finkelstein, David I. ;
Bolli, Reinhard ;
Miescher, Sylvia M. .
PLOS ONE, 2013, 8 (05)
[5]  
Eli Lilly and Company, 2012, COMMUNICATION
[6]   IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway [J].
Gong, Bing ;
Pan, Yong ;
Zhao, Wei ;
Knable, Lindsay ;
Vempati, Prashant ;
Begum, Shimul ;
Ho, Lap ;
Wang, Jun ;
Yemul, Shrishailam ;
Barnum, Scott ;
Bilski, Amanda ;
Gong, Ben Y. ;
Pasinetti, Giulio M. .
MOLECULAR IMMUNOLOGY, 2013, 56 (04) :619-629
[7]   Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells [J].
Israel, Mason A. ;
Yuan, Shauna H. ;
Bardy, Cedric ;
Reyna, Sol M. ;
Mu, Yangling ;
Herrera, Cheryl ;
Hefferan, Michael P. ;
Van Gorp, Sebastiaan ;
Nazor, Kristopher L. ;
Boscolo, Francesca S. ;
Carson, Christian T. ;
Laurent, Louise C. ;
Marsala, Martin ;
Gage, Fred H. ;
Remes, Anne M. ;
Koo, Edward H. ;
Goldstein, Lawrence S. B. .
NATURE, 2012, 482 (7384) :216-U107
[8]   Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity [J].
Jack, Clifford R., Jr. ;
Wiste, Heather J. ;
Weigand, Stephen D. ;
Knopman, David S. ;
Lowe, Val ;
Vemuri, Prashanthi ;
Mielke, Michelle M. ;
Jones, David T. ;
Senjem, Matthew L. ;
Gunter, Jeffrey L. ;
Gregg, Brian E. ;
Pankratz, Vernon S. ;
Petersen, Ronald C. .
NEUROLOGY, 2013, 81 (20) :1732-1740
[9]   Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade [J].
Jack, Clifford R., Jr. ;
Knopman, David S. ;
Jagust, William J. ;
Shaw, Leslie M. ;
Aisen, Paul S. ;
Weiner, Michael W. ;
Petersen, Ronald C. ;
Trojanowski, John Q. .
LANCET NEUROLOGY, 2010, 9 (01) :119-128
[10]   The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics [J].
Karran, Eric ;
Mercken, Marc ;
De Strooper, Bart .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (09) :698-U1600